MedTrace Logo

Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception

NCT02238379 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-01-17

Study results available
· View outcomes & findings →

Summary

The objective of this study is to investigate the effects of oxytocin on social behavior and brain activity using EEG and the event-related potential (ERP) technique. The value of EEG is its high temporal specificity, enabling precision in the timing of social behavior to be addressed. In order to elicit social responses in the human brain, a variety of social and emotional visual stimuli will be presented during EEG recording, namely infant and adult faces and houses. Brain responses after intranasal oxytocin will then be compared with placebo, to examine the effect of intranasal oxytocin on central nervous system activity. We hypothesize that intranasal oxytocin will enhance the neural response to social stimuli (infant and adult faces) but not to non-social stimuli (houses).

Conditions

  • Social Perception

Interventions

DRUG

Oxytocin

24 International Units of Oxytocin in a Nasal Spray

OTHER

Placebo

Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.

Sponsors & Collaborators

  • Anna Freud

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Linda C Mayes, MD · Yale University

  • Helena JV Rutherford, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238379 on ClinicalTrials.gov